Mesoblast revenue jumps sevenfold to $120m as Ryoncil turns cell therapy into a commercial business

Mesoblast Limited (NASDAQ: MESO; ASX: MSB) has completed its first full fiscal year as a commercial-stage cell-therapy company with total revenue rising to US$120.3 million from US$17.2 million, driven overwhelmingly by the U.S. launch of Ryoncil for pediatric steroid-refractory acute graft-versus-host disease. Ryoncil generated US$115.2 million of net product revenue after a 13.4% gross-to-net adjustment, meaning the newly launched product contributed almost 96% of Mesoblast’s total fiscal 2026 revenue. Reported gross profit reached US$103.6 million while the attributable net loss narrowed 44% to US$57.5 million from US$102.1 million.

The result represents a structural change in Mesoblast’s financial model because a company that had historically depended primarily on capital markets and partnership income now has a commercial product generating more than US$100 million annually. Net operating cash spend declined to US$43.8 million for the year and to only US$13.4 million during the second half, while Mesoblast ended June with approximately US$103 million of cash and a new US$125 million five-year credit facility that consolidated and refinanced higher-cost borrowings. The company is simultaneously reinvesting heavily in clinical development, with R&D expense rising to US$97.5 million as it pursues Ryoncil label expansion and late-stage programmes in chronic low back pain and heart failure.

The commercial momentum creates a different investment question from the one Mesoblast faced before Ryoncil approval. The issue is no longer simply whether an allogeneic mesenchymal stromal cell therapy can reach the U.S. market, because that regulatory hurdle has been cleared and Ryoncil has already established meaningful sales. The next challenge is whether the company can use that revenue base to expand Ryoncil into larger patient populations while avoiding the need for repeated highly dilutive financing as its broader pipeline moves through expensive registrational programmes.

How strong was Ryoncil’s first full year in the U.S. market?

Ryoncil generated US$115.2 million of fiscal-year net revenue, compared with Mesoblast’s earlier full-year expectation of approximately US$110 million-US$120 million. The product therefore finished within the upper half of the company’s guidance range and accelerated into year-end, producing approximately US$36 million of net revenue in the June quarter alone. Annualizing that fourth-quarter figure would imply a run rate of about US$144 million, although a single quarter should not be treated as a formal forecast because ordering patterns, patient numbers and reimbursement can vary.

Commercial adoption widened considerably during the year. Mesoblast onboarded more than 50 U.S. pediatric transplant centres, including 14 of the 15 largest centres that collectively account for nearly half of pediatric transplant volumes, while reimbursement access expanded to more than 280 million covered lives across commercial and government payers. The median time from patient identification to treatment initiation fell from 29 days at launch to eight days, suggesting that hospital processes, reimbursement pathways and product logistics became substantially more efficient as institutions gained experience using the therapy.

Those operational metrics matter because cell therapies can face commercial bottlenecks that ordinary pharmaceuticals do not, including site onboarding, specialist handling, hospital reimbursement and coordination between transplant centres and distributors. Ryoncil is an off-the-shelf cryopreserved therapy rather than a patient-specific manufactured product, which can simplify deployment compared with autologous cell therapies, but successful commercialization still requires centres to build treatment pathways around the product. Mesoblast’s first-year numbers suggest that infrastructure has now been established across much of the relevant U.S. pediatric transplant network.

Why could adult graft-versus-host disease be much larger than the current Ryoncil market?

Ryoncil is currently approved in the United States for pediatric patients aged two months and older with steroid-refractory acute graft-versus-host disease. Mesoblast is now pursuing adult use through two strategic routes: third-line treatment after failure of ruxolitinib or other agents, and a registrational programme combining Ryoncil with ruxolitinib in second-line Grade III or IV disease. The company estimates the adult opportunity is approximately three times the size of the pediatric market, which means successful label expansion could materially alter Ryoncil’s commercial ceiling.

Mesoblast has already begun enrolling the second-line adult registration study and expects to activate as many as 40 U.S. sites representing approximately 60% of the roughly 8,500 annual adult allogeneic bone-marrow transplant population. The company has also presented third-line data showing 76% Day 100 survival in adolescents and adults treated with Ryoncil after failure of ruxolitinib or other agents, compared with historical survival rates of 20%-30% cited by Mesoblast from the literature. Those cross-study historical comparisons cannot substitute for a randomized registration trial, but they explain why the company sees a clinical and regulatory rationale for expanding beyond pediatrics.

If adult approval eventually produced a market roughly three times larger than the existing pediatric opportunity, Ryoncil’s present US$115 million annual revenue base could become only the first stage of the franchise. That does not imply a simple threefold revenue forecast because treatment rates, pricing, competition and reimbursement may differ significantly between children and adults. The strategic significance lies in the possibility that the same commercial manufacturing and hospital infrastructure can support a considerably larger label without Mesoblast having to launch an entirely new product.

How much has the Ryoncil launch changed Mesoblast’s profitability?

Revenue increased by approximately US$103.1 million from fiscal 2025 to fiscal 2026, while reported gross profit reached US$103.6 million and gross profit excluding marketed-intangible amortization was US$109.7 million. With cost of revenue of US$16.7 million against US$120.3 million of total revenue, the reported gross margin was approximately 86%, although part of Mesoblast’s revenue includes royalty income and the company’s stated gross-profit measure incorporates its accounting treatment of marketed intangible assets.

The high gross profit has not yet translated into company-wide profitability because Mesoblast is deliberately reinvesting in clinical programmes and commercialization. Research and development expense rose to US$97.5 million from US$34.8 million, while selling, general and administrative costs increased to US$57.3 million from US$39.3 million. Finance costs remained substantial at US$23.8 million, resulting in a US$57.5 million attributable net loss even after the revenue transformation.

The loss nevertheless narrowed by approximately US$44.6 million, or 44%, despite the much larger R&D programme. The second half showed a more pronounced improvement, with net loss falling to US$17.3 million and operating cash spend declining to US$13.4 million. Those numbers suggest Ryoncil is beginning to fund a meaningful portion of Mesoblast’s development activity, although the company has not yet reached the point where commercial cash generation fully covers R&D, overhead and financing costs.

Why is the 350-patient back pain trial potentially bigger than Ryoncil?

Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with inflammatory degenerative disc disease. The study was expanded from 300 to 350 treated patients after investigator demand, and top-line results are expected around mid-2027 after the final patient completes 12 months of follow-up. The primary endpoint is intended to confirm durable pain reduction from a single intradiscal injection, with secondary measures covering function, quality of life and reduced use of pain medication including opioids.

Mesoblast estimates more than seven million people in the United States have the relevant form of chronic low back pain and describes the addressable market as exceeding US$10 billion. Those are company estimates rather than guaranteed commercial outcomes, and the Phase 3 trial still needs to demonstrate statistically and clinically meaningful benefit before regulatory approval becomes possible. Even so, the size of the indication means a positive result could produce a substantially larger commercial opportunity than Ryoncil’s current pediatric GVHD market.

The programme also creates binary clinical risk within an otherwise improving financial story. Mesoblast is spending heavily to support rexlemestrocel-L development, and a successful trial could validate another major use for its cell-therapy platform, while a negative outcome would remove one of the company’s largest projected future markets. Ryoncil revenue provides financial cushioning that did not exist during earlier Mesoblast trials, but it does not remove the importance of the 2027 back-pain readout.

What other Ryoncil and rexlemestrocel-L catalysts are moving forward?

Mesoblast has FDA clearance to proceed directly into a registrational trial of Ryoncil in ambulatory children aged five to nine with Duchenne muscular dystrophy, an indication affecting approximately 15,000 U.S. children according to the company. The programme represents another potential label expansion for the same remestemcel-L platform, although clinical efficacy and regulatory success remain to be demonstrated. Mesoblast is also continuing work on inflammatory bowel disease and other inflammatory conditions as part of the broader remestemcel-L strategy.

Rexlemestrocel-L is being developed separately for cardiovascular disease. Mesoblast has received an FDA BLA filing number and requested modular review for a proposed indication involving prevention of life-threatening gastrointestinal bleeding associated with right ventricular dysfunction in patients with end-stage heart failure supported by a left ventricular assist device. Discussions with the FDA around the modular-review process are expected to continue, meaning the programme is more advanced regulatorily than an early clinical project but has not yet reached an approved filing outcome.

The company is also moving into next-generation engineered mesenchymal stromal-cell technologies, including chimeric antigen receptor modified MSCs and oncolytic-virus-loaded MSCs. Those programmes are substantially earlier than Ryoncil and rexlemestrocel-L and should not be valued as near-term commercial assets, but they demonstrate that Mesoblast intends to use commercial revenue from its first product to broaden rather than narrow its development portfolio.

Does Mesoblast’s $103m cash balance provide enough flexibility?

Mesoblast ended June with approximately US$103 million of cash compared with US$161.6 million a year earlier, while net operating cash spend for fiscal 2026 was US$43.8 million. Using the historical annual cash-spend figure mechanically would suggest more than two years of coverage from the year-end cash balance alone, but that would be an unreliable runway calculation because development spending, Ryoncil revenue, debt service and clinical-trial activity are all changing materially. The more useful conclusion is that Mesoblast now has both cash resources and a commercial revenue stream supporting operations rather than depending exclusively on external equity.

The new US$125 million five-year credit facility also changes the financing structure because it consolidates and retires two higher-cost facilities without issuing new equity. Debt financing carries interest and repayment obligations, so describing it as non-dilutive does not mean it is free capital, but it gives Mesoblast another source of liquidity without increasing the share count. Finance costs of US$23.8 million during FY26 demonstrate that reducing the cost of capital remains commercially important even as product sales expand.

The main financial question is whether Ryoncil growth can outrun the company’s rising R&D budget. Fiscal 2026 provides the first evidence that this is possible: revenue increased more than sevenfold, gross profit exceeded US$100 million, net loss fell 44% and second-half cash spending declined sharply. Fiscal 2027 now needs to show that those improvements continue while Mesoblast simultaneously pays for adult GVHD studies and reaches the pivotal rexlemestrocel-L back-pain readout.

What has changed most fundamentally for Mesoblast?

The company has crossed from a development-stage biotechnology story into one where commercial execution can be measured every quarter. Ryoncil generated more than US$115 million in its first full U.S. year, reached leading transplant centres and obtained reimbursement access across more than 280 million covered lives, giving Mesoblast an operating base that did not exist before FDA approval. That commercial foundation reduces, but does not eliminate, the financing risk associated with its unusually broad late-stage pipeline.

The next value creation steps are also larger than the initial pediatric indication. Adult GVHD could materially expand the Ryoncil franchise, while the 350-patient chronic low back pain trial addresses a population measured in millions rather than thousands. The company is consequently moving into a phase where execution across manufacturing, hospital adoption and clinical development matters simultaneously rather than sequentially.

That creates a more balanced but also more demanding investment case. Mesoblast now has a product that can fund part of its ambition, but R&D spending has risen sharply because the company is attempting to convert that first regulatory success into a broader commercial cell-therapy platform. Whether FY26 proves to be the beginning of self-funded expansion or merely a strong launch year will depend on continued Ryoncil growth and the clinical milestones arriving over the next twelve to eighteen months.